Bicara Therapeutics (BCAX) Total Non-Current Liabilities (2023 - 2024)
Bicara Therapeutics posted quarterly Total Non-Current Liabilities of $18.1 million for Q4 2024, up 17.23% year-on-year from $15.5 million in Q1 2024, and up 23.96% on a QoQ basis from $14.6 million in Q3 2024.
Bicara Therapeutics (BCAX) has 2 years of Total Non-Current Liabilities data on file, last reported at $18.1 million in Q4 2024.
- For the quarter ending Q4 2024, Total Non-Current Liabilities rose 17.23% year-over-year to $18.1 million; the trailing twelve-month figure through Dec 2024 stood at $18.1 million (up 17.23% YoY), and the FY2024 full-year result was $18.1 million, up 17.23% from the prior year.
- Total Non-Current Liabilities for Q4 2024 stood at $18.1 million, up from $14.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $18.1 million in Q4 2024 and bottomed at $14.6 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Bicara Therapeutics | 1.25 Bn | 1.25 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 18.12 Mn |
| Sep 30, 2024 | 14.62 Mn |
| Dec 31, 2023 | 15.46 Mn |